In this edition:
- Strategic Evolution
- Extension of Janssen Collaboration
- Monetisation of Assets
- The Potential for Peptide Therapeutics
- Unique Attributes of Phylomers
- Meaningful Platform Enhancements
- Our Inside Edge for Intracellular Targets
- Strengthened Financial Position
We have waited longer than usual since our last newsletter to update shareholders so that we could complete our discussions with Janssen relating to an extension of our collaboration, announced on 31 January 2013. We also wanted to finalise our plans for technology enhancements over the next 12 months, which represent key value-adding milestones, and are set out in our new guidance of anticipated news flow.
To view Newsletter please download PDF below:
